4Q0A image
Deposition Date 2014-04-01
Release Date 2014-07-02
Last Version Date 2024-02-28
Entry Detail
PDB ID:
4Q0A
Keywords:
Title:
Vitamin D Receptor complex with lithocholic acid
Biological Source:
Source Organism:
Danio rerio (Taxon ID: 7955)
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.90 Å
R-Value Free:
0.24
R-Value Work:
0.21
R-Value Observed:
0.21
Space Group:
P 65 2 2
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Vitamin D3 receptor A
Gene (Uniprot):vdra
Chain IDs:A (auth: C)
Chain Length:302
Number of Molecules:1
Biological Source:Danio rerio
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Nuclear receptor coactivator 2
Gene (Uniprot):NCOA2
Chain IDs:B (auth: D)
Chain Length:10
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Structural insights into the molecular mechanism of vitamin d receptor activation by lithocholic Acid involving a new mode of ligand recognition.
J.Med.Chem. 57 4710 4719 (2014)
PMID: 24818857 DOI: 10.1021/jm5002524

Abstact

The vitamin D receptor (VDR), an endocrine nuclear receptor for 1α,25-dihydroxyvitamin D3, acts also as a bile acid sensor by binding lithocholic acid (LCA). The crystal structure of the zebrafish VDR ligand binding domain in complex with LCA and the SRC-2 coactivator peptide reveals the binding of two LCA molecules by VDR. One LCA binds to the canonical ligand-binding pocket, and the second one, which is not fully buried, is anchored to a site located on the VDR surface. Despite the low affinity of the alternative site, the binding of the second molecule promotes stabilization of the active receptor conformation. Biological activity assays, structural analysis, and molecular dynamics simulations indicate that the recognition of two ligand molecules is crucial for VDR agonism by LCA. The unique binding mode of LCA provides clues for the development of new chemical compounds that target alternative binding sites for therapeutic applications.

Legend

Protein

Chemical

Disease

Primary Citation of related structures